Spring Bank Pharmaceuticals Appoints Scott Smith as Chairman of the Board
December 18, 2018 16:15 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Pharmaceuticals Hosts R&D Day on Pipeline of Novel Immunomodulatory Therapeutics
December 06, 2018 07:00 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Announces Additional Pre-Clinical Data on Its Second-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy
November 29, 2018 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Announces Additional Inarigivir Results at AASLD Conference
November 09, 2018 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
*Results from full 24 weeks of dosing from the first three cohorts of the ongoing Phase 2 ACHIEVE trial in hepatitis B to be highlighted *New data from ACHIEVE trial demonstrates that increased...
Spring Bank Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences
November 05, 2018 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Announces Three Poster Presentations on Its Next-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy
November 01, 2018 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Pharmaceuticals to Host R&D Day on Thursday, December 6, 2018
October 29, 2018 11:00 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Pharmaceuticals Reports Third Quarter Financial Results
October 25, 2018 16:30 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Announces Inarigivir Data Presentations at AASLD Conference
October 03, 2018 17:02 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference
September 17, 2018 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...